News
 
 
 
> News > News
BioAsia 2012, Hyderabad, India
» File :
BioAsia-2012.pdf (1.35 MB)
» HomePage : http://www.2012.bioasia.in
» Link :

BioAsia

 BioAsia 2012A Global Confluence of the Who’s Who of LifeSciences Industry

  

Biotechnology today has evolved from a science to impacting human life in more ways than one. Paradigm shifts, dynamic changes and interplay between West and East in terms of capital innovation to bring about the much needed sync between biotech research and biobusiness have opened innumerable possibilities. BioAsia 2012’s vision is to further the cause of LifeScience by enabling a global confluence of key industry stakeholders and thought leaders by creating synergies between biotech & biopharma companies, venture capitalists, policy makers, CROs, research institutions, scientific organizations and academia.

 

BioAsia 2012 - Vibrant theme of “Optimizing Opportunities”

 

From February 9th   to 11th, 2012, BioAsia 2012 will unfold its ninth chapter on a vibrant international platform with the vibrant theme of “Optimizing Opportunities”. BioAsia 2012 has identified 4 key focus areas - viz. Vaccines, Contract Research, Investments and Intellectual Property Rights (IPR) that will drive synergies amongst key stakeholders and participants. BioAsia 2012 intends to focus on all four key areas in the context of changing trends, continuous challenges, potential for growth and future development. The forum will witness industry key stakeholders and thought leaders exchange meaningful dialogue, knowledge sharing and provide networking and biobusiness opportunities besides providing participants an exclusive opportunity to exhibit, launch and showcase their unique strengths, products and services.

 

The event will focus on the Health, Pharmaceutical and Agribiotech sectors covering areas viz. Challenges faced by Pharmaceutical Industry moving towards Biotechnology sector and the reason to do so; Future of Biotech Industry in India; Global Biotech companies Vs. Asian biotech companies: Are we there?; Experience/ Challenges/ Changes faced by International companies in Indian Biotech market; Biotech Products in India; and Indian Competitive Edge in Biotech sector. Other areas that will be focused includes Small Molecule Therapeutics, Generics to Innovative Drugs, Bioinvestment, Bio-Infrastructure, Bio-Incubators, Vaccines, Regenerative Medicine, Oncology, Medical Devices, Diagnostics, Biotech Crops, Issues & Challenges in the Asian Seed Industry, Biofuels , Climate Change, etc.

 

 

BioAsia – The Global Bio Business Forum

 

BioAsia over the years has emerged as a Global Brand and has been offering the most sought platform for convergence of the business leaders, policy makers, investors, etc. The eighth edition of the event was held in February 2011, which witnessed a participation of over 2500

delegates from 38 countries from across the globe. The event also realized 400 onsite B2B meetings and featured about 360 companies.

 

BioAsia has been extremely successful in bringing together the who’s who of biotech and biopharma across the globe. Participant profile of event reflects the attendance of key decision makers of the industry. The unique strength of BioAsia has been the strong network of FABA directly reaching out to 20 Asian countries and 15 Non-Asian Countries. The event has evolved as a must attend events in our partners calendars. Major areas of strength of BioAsia over other similar events includes workshops, biopark sessions(Genome Valley visit), Biobazaar(International Buyer Seller Meet), CEO Conclave, Award ceremony, high profile speakers from the top Lifescience, massive media coverages, strong participation from all major Asian and non-Asian countries, support from organizations based out of Italy, Spain, USA, Germany, UK, etc. Not only this, BioAsia facilitated several new projects in the year

2011, including Lonza Knowledge Centre(Switzerland), Lepakshi Knowledge Hub, Sri Bio Integrated Discovery Centre, and Tran-Scell Biologics, a unit of Pacific Hospital for stem cell banking and research in Hyderabad. Renaissance and Biogenesis Project on Cancer Hospital and Research Centre were also announced at BioAsia 2011. These projects are expected to bring in investment of INR 2500 crores in Hyderabad.

 

Another highlight component of BioAsia is the Genome Valley Excellence Award. The award has gained high recognitions and has been considered as one of the most prestigious awards. The

recipient history includes Dr. Martin Mackay (Global R&D President, Pfizer), Prof. Martin J. Evans (Nobel Laureate, Cardiff University, UK), Prof. Marc Van Montagu (Institute of Plant Biotechnology in Developing Countries, Belgium), Prof. G. Padmanaban (Fr. Director, Indian Institute of Science, Bangalore), Prof. M. S. Swaminathan (Chairman, MSSRF, Chennai), etc. In order to recognize the young scientists below the age of 35 years who have done extraordinary research in any area of life sciences and who have created a product of applied value or enervated a product of utility for the welfare of human society, was first introduced in the year 2007, which was named after the Late Honorable Chief Minister, Dr.Y.S. R. Rajasekhar Reddy as Dr. YSR BioAsia Innovation Award after his accidental death and in order to promote investigative spirit in young school children, BioAsia Young Minds Award was instituted in the year 2009 for schoolchildren of class 10th, 11th and 12th standards.

 

No Subject File
18 Inaugural Message
17 YABEC 2012 will be held in the University of Tokushima, Tokushima, on October 26th - 28th, 2012
16 AFOB Signs Collaboration Agreement with the Wiley-Blackwell
15 Ho Nam Chang appointed the 2nd AFOB President
14 IBS 2012 Early-bird registration is extended!
13 Abstract submission deadline for poster extended to May 20th!!
12 IBS 2012 (abstract submission deadline for oral presentation by March 09th)
BioAsia 2012, Hyderabad, India
10 The 3rd Regional Symposium in Vietnam
9 YABEC 2011
   1  ·  2  ·  3  ·  4   
403, Get-Pearl Tower 12, Gaetbeol-ro, Yeonsu-gu,Incheon 21999, Korea
TEL : +82-32-260-0066 | FAX : +82-32-260-0897